PT
Autoridade da Concorrência

Case details

Print
Merger control
Case reference
CCENT/2008/54 - CSL Limited / Talecris
Acquiring
CSL Limited
Description
the parent company of the CSL group; it is active in the biopharmaceutical area, researching, developing, producing, marketing and distributing various products derived from human plasma.
Acquired
Talecris
Description
operates in the field of biotherapeutics and biotechnology; it researches, develops and produces critical treatments for Alfa-1 deficiency, under the trade mark Polastin.
Sector
  • Extractive and manufacturing Industries
Activity (NACE)
  • C21 - Manufacture of basic pharmaceutical products and pharmaceutical preparations
Applicable legislation
Art. 9(1)(a) (Law 18)
Notification thresholds
Market share
Type of merger
Vertical
Cooperation with sector regulators
Status
Closed
Type of Investigation
Phase 1
AdC’s decision
Case description
Notified on 22 August 2008, with effect on 29 September 2008, this merger operation consists of the acquisition by CSL Limited (henceforth "CSL Limited") of exclusive control of Talecris Biotherapeutics Holdings Corp. (henceforth "Talecris") and all its subsidiaries, including Talecris Biotherapeutics Inc, which operates in Portugal through its distributor RV Raul Vieira Biotecnologia SA.
Timeline
2008-12-12
COMPETITION AUTHORITY adopts decision of non-opposition to CSL Limited/Talecris Biotherapeutics merger
2008-10-07
Publication of the announcement
Click here to see your activities